

FLORIDA DEPARTMENT OF Environmental Protection

Ron DeSantis Governor

Jeanette Nuñez Lt. Governor

Shawn Hamilton Secretary

Bob Martinez Center 2600 Blair Stone Road Tallahassee, FL 32399-2400

HEALTHCARE FACILITIES

40 CFR 266 Subpart P – Hazardous Waste Pharmaceuticals

Fa	cility Name:	Date:			
Facility Representative: Facility		Facility ID #:			
Em	nail Addresss:	Inspector:			
	NOTIFICATION REQUIREMENTS				
1.	Has the healthcare facility notified that it is operating under Par as required by 40 CFR 266.502(a)(1) using form 8700-12FL?	t 266 Subpart P	Y	N	_ N/A
	Note: Until DEP updates the 8700-12FL Form, the Federal 8700-12 F required.	orm will be			
2.	If the healthcare facility already had an EPA ID number on 8/x required to file a biennial report, was the 8700-12FL submitted [266.502(a)(1)(i)]		Y	N	_ N/A
3.	If the healthcare facility already had an EPA ID number on 8/x required to file a biennial report, was the 8700-12FL submitted or within 60 days of the facility becoming subject to Subpart P?	by October xx, 2019,	Y	N	_ N/A
4.	If the healthcare facility did not have an EPA ID number on 8/xx 8700-12FL submitted by October xx, 2019, or within 60 days o subject to Subpart P? [266.502(a)(1)(ii)]		Y	N	_ N/A
5.	Is a copy of the 8700-12FL maintained in the facility's files for a healthcare facility is subject to Subpart P? [266.502(a)(1)(iii)]	is long as the	Y	N	_ N/A
6.	If the healthcare facility's generator status becomes VSQG and withdraw from Subpart P, did the facility submit an 8700-12FL operating as a VSQG under 40 CFR 262.14? [266.502(a)(2)(i)]		Y	N	_ N/A
7.	Is a copy of the 8700-12FL maintained in the facility's files for 3 of the signature on the notification of its withdrawl from Subpart		Y	N	_N/A
	GENERAL STANDARDS – NON-CREDITABLE	HW PHARMACEUTIC	ALS		
8.	Has the healthcare facility correctly determined whether the non- pharmaceuticals generated are hazardous waste pharmaceuticals NOTE : A healthcare facility that manages all of its non-creditable non- as non-creditable HW pharmaceuticals is not required to keep docume waste determinations	als? [266.502(c)] h-HW pharmaceuticals	Y	N	N/A
9.	If the healthcare facility had a spill of non-creditable HW pharm spill cleaned up immediately and the cleanup material manage pharmaceuticals? [266.502(k)]		Y	N_	N/A
10.	Does the healthcare facility comply with the land disposal restriving with the requirements of 40 CFR 268.7(a), except that EPA was required on the LDR notification? [266.502(g)]		Y	_N	N/A

Effective 9/2022

- 11. Are all employees managing non-creditable HW pharmaceuticals thoroughly familiar with proper waste handling and emergency procedures relevant to their responsibilities during normal facility operations and emergencies? [266.502(b)]
- 12. Does the healthcare facility ensure hazardous waste pharmaceuticals are not discharged to a sewer system that passes through to a publicly owned treatment works (POTW)? [266.505]

RECORDKEEPING – NON-CREDITABLE HW PHARMACEUTICALS

- 13. Does the healthcare facility keep a copy of each manifest signed in accordance with 40 CFR 262.23(a) for 3 years or until it receives a signed copy from the designated facility which received the non-creditable HW pharmaceuticals? This signed copy must be retained as a record for at least 3 years from the date the waste was accepted by the initial transporter. [266.502(j)(1)]
- 14. Does the healthcare facility keep a copy of each exception report for a period of at least 3 years from the date of the report? [266.502(j)(2)]
- 15. Does the healthcare facility keep records of any test results, waste analyses, or other determinations made to support its hazardous waste determination(s) consistent with 40 CFR 262.11(f), for at least 3 years from the date the waste was last sent to onsite or off-site treatment, storage or disposal? [266.502(j)(3)]
- 16. Are all records readily available upon request by the inspector? [266.502(j)(5)]

NON-CREDITABLE HW PHARMACEUTICALS – STORAGE REQUIREMENTS

- 17. Are non-creditable HW pharmaceuticals only stored in containers that are structurally sound, compatible with the contents, and that lack evidence of leakage, spillage, or damage that could cause leakage? [266.502(d)(1)] N 18. Are containers of ignitable, reactive, or co-mingled incompatible non-creditable HW pharmaceuticals managed to prevent the potential to generate extreme heat or pressure, fire or explosion, or violent reaction? [266.502(d)(2)(i)] 19. Are containers of ignitable, reactive, or co-mingled incompatible non-creditable HW pharmaceuticals managed to prevent the potential to produce uncontrolled toxic mists, fumes, dusts, or gases in sufficient quantities to threaten human health? 20. Are containers of ignitable, reactive, or co-mingled with incompatible non-creditable HW pharmaceuticals managed to prevent the potential to produce uncontrolled flammable fumes or gases in sufficient quantities to pose a risk of fire or explosion?
- 21. Are containers of ignitable, reactive, or co-mingled incompatible non-creditable HW pharmaceuticals managed to prevent the potential to damage the structural integrity of the container? [266.502(d)(2)(iv)]


[266.502(d)(2)(ii)]

[266.502(d)(2)(iii)]

- 22. Are containers of ignitable, reactive, or co-mingled incompatible non-creditable HW pharmaceuticals managed to prevent the potential to threaten human health or the environment? [266.502(d)(2)(v)]
- 23. Are containers of non-creditable HW pharmaceuticals kept closed and secured in a manner that prevents unauthorized access to the contents? [266.502(d)(3)]

Y____N___N/A

N N/A




N/A

N N/A

Y N N/A


Y N







____ N___ N/A_



Y N _____N/A___

	Facility:			
	Date:			
24.	Does the healthcare facility accumulate non-creditable HW pharmaceuticals prohibite from being combusted because of the dilution prohibition of 268.3(c) in separate containers that are labeled with all applicable EPA waste codes? [266.502(d)(4)]	ed Y	N	N/A
	[NOTE : The hazardous waste pharmaceuticals not suitable for incineration include characteris D043) as well as the listed wastes U151 (mercury), U205 (selenium sulfide), and P012 (arser contain greater than 1% total organic carbon.]			
25.	Are containers of non-creditable HW pharmaceuticals clearly marked or labeled "Hazardous Waste Pharmaceuticals"? [266.502(e)]	Y	_ N	_ N/A
26.	Are containers of non-creditable HW pharmaceuticals stored on-site for one year or less? [266.502(f)(1)]	Y	N	N/A
27.	How does the healthcare facility demonstrate non-creditable HW pharmaceuticals were stored on-site for one year or less?			
	Marking or labeling the container of non-creditable HW pharmaceuticals with the date the non-creditable pharmaceuticals became a waste? $[266.502(f)(2)(i)]$; Y	_ N	N/A
	Maintaining an inventory system that identifies the date the non-creditable HW pharmaceuticals first became a waste? [266.502(f)(2)(ii)]	Y	_ N	N/A
	Placing the non-creditable HW pharmaceuticals in a specific area and identifying the earliest date that any of the non-creditable HW pharmaceuticals in the area became a waste? [266.502(f)(2)(iii)]			
	ACCEPTING NON-CREDITABLE HW PHARMACEUTICALS FR	OM OF	F-SITE	N/A
	VSQG HEALTHCARE FACILITY			
28.	If the healthcare facility is receiving non-creditable HW pharmaceuticals from an off-s VSQG healthcare facility, is the receiving facility under the control of the same perso (as defined in § 260.10) as the VSQG healthcare facility that is sending the non-cred HW pharmaceuticals off-site or has a contractual or other documented business relationship whereby the receiving healthcare facility supplies pharmaceuticals to the very small quantity generator healthcare facility? [266.502(I)(1)]	on litable	N	N/A
29.	If the healthcare facility is receiving non-creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility operating under 40 CFR Part 266 Subpart P for its non-creditable HW pharmaceuticals? [266.502(I)(2)]	Y	N	N/A
30.	If the healthcare facility is receiving non-creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility managing the non-creditable HW pharmaceuticals it receives from off-site in compliance with 40 CFR Part 266 Subpart P? [266.502(I)(3)]		N	N/A
31.	If the healthcare facility is receiving non-creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility keeping records of the non-creditable HW pharmaceutical shipments it receives for 3 years from the date the shipment is received? [266.502(I)(4)]	Y	N	N/A

	Facility:			
	Date:			
	PRE-TRANSPORT REQUIREMENTSN/A			
	If the transporter is not on-site during the inspection, then this section is usua	lly "N	/ A ."	
	If waste has been improperly transported off-site the requirements in this section	on ap	ply.	
32.	. Has the healthcare facility packaged the non-creditable hazardous waste pharmaceuticals for shipment in accordance with the applicable DOT regulations under 49 CFR parts 173, 178, and 180? [266.508(a)(1)(i)]	Y	_ N	_N/A
	49 CFR 173 – Shippers – General Requirements for Shipments and Packagings 49 CFR 178 – Specifications for Packagings 49 CFR 180 – Continuing Qualification and Maintenance of Packagings			
33.	. Has the healthcare facility labeled each package for shipment in accordance with the applicable DOT regulations under 49 CFR Part 172 Subpart E – diamond-shaped DOT hazard class container label? [266.508(a)(1)(ii)]	Υ	_ N	_ N/A
34.	. Has the healthcare facility marked each package for shipment in accordance with the applicable DOT regulations under 49 CFR Part 172 Subpart D – correct DOT shippin name and UN, NA, or ID number? [266.508(a)(1)(iii)(A)]		_ N	_N/A
35.	. Has the healthcare facility marked each container of 119 gallons or less used in transportation with the following words and information in accordance with 49 CFR 172.304? [266.508(a)(1)(iii)(B)]	Y	_ N	_ N/A
	HAZARDOUS WASTE—Federal Law Prohibits Improper Disposal. If found, contact the nearest police or public safety authority or the U.S. Environmental Protection Agency.			
	Healthcare Facility's or Reverse distributor's Name and Address Healthcare Facility's or Reverse distributor's EPA Identification Number Manifest Tracking Number			
36.	Has the healthcare facility marked each lab pack containing non-creditable hazardou waste pharmaceuticals that will be incinerated in compliance with 40 CFR 268.42(c) the EPA waste codes D004, D005, D006, D007, D008, D010, and D011, where applicable? [266.508(a)(1)(iii)(B)]	with	_N	_ N/A
	NOTE : A nationally recognized electronic system, such as bar coding or radio frequency identification, may be used to identify the EPA Hazardous Waste Number(s).			
37.	. Has the healthcare facility placarded or offered the initial transporter the appropriate			

placards according to DOT regulations for hazardous materials under 49 CFR Part 172 Subpart F? [266.508(a)(1)(iv)]

Y____N___N/A____

5

Facility:_____ Date:_____

SHIPPING NON-CREDITABLE HW PHARMACEUTICALS THE MANIFEST

38.	Does the healthcare facility use a paper manifest (EPA Form 8700-22; OMB #2050-0039) for off-site shipment(s) of hazardous wastes pharmaceuticals? [262.20(a)(1)]	Y	_ N	N/A
39.	Does the healthcare facility use an electronic manifest for off-site shipment(s) of hazardous wastes pharmaceuticals that complies with the e-manifest requirements of 40 CFR 262.24 [262.20(a)(3)]	Y	_ N	N/A
40.	Does the manifest contain the word "PHARMS" in Item 13? [266.508(a)(2)(ii)]	Y	_N	_N/A
41.	Are all manifest fields on the paper manifest, other than Item 13 "Waste Codes," filled out correctly? [262.20(a)(1)]	Y	_N	_N/A
42.	Are all manifest fields on the electronic manifest, other than Item 13 "Waste Codes," filled out correctly? [262.20(a)(3)]	Y	_N	_ N/A
43.	Does the facility ship by water or rail? [If so, check 262.23(c) and (d)]	Y	_N	_N/A

NOTE: If any manifest discrepancies are noted, please describe in narrative.

Identify manifest document numbers and dates of manifests with errors below:

Manifest #	Date	Destination	Error(s)

REJECTED LOADS NON-CREDITABLE HW PHARMACEUTICALS _____ N/A

- 44. If the healthcare facility received a rejected shipment of non-creditable HW pharmaceuticals back in accordance with the manifest discrepancy provisions of 40 CFR 264.72 or 265.72 was the returned shipment managed in accordance with the requirements of 40 CFR 266(502(d) and (e)? [266.502(h)]
- 45. Upon receipt of the rejected shipment of non-creditable HW pharmaceuticals did the facility sign either; (i) Item 18c of the original manifest, if the original was used for the returned shipment; or (ii) Item 20 of the new manifest, is a new manifest was used for the returned shipment? [266.502(h)(1)]
- 46. Upon receipt of the rejected shipment of non-creditable HW pharmaceuticals did the facility provide the transporter a copy of the manifest? [266.502(h)(2)]
- 47. Within 30 days of receipt of the rejected shipment, did the facility send a copy of the manifest to the designated facility that returned the shipment? [266.502(h)(3)]
- 48. Within 90 days of receipt of the rejected shipment, did the facility transport, or offer for transport the returned shipment in accordance with the shipping standards of 40 CFR 266.508(a)? [266.502(h)(4)]
- 49. If the healthcare facility did not receive a copy of the manifest signed by the designated facility within 60 days of the date the non-creditable HW pharmaceuticals were accepted by the initial transporter, did the healthcare facility submit a legible copy of the original manifest, indicating that the healthcare facility has not received confirmation of delivery, to DEP? [266.502(i)(2)(i)(A)(1)]
 Y____N___N/A_

	·		
ie ne for			
	Y	_ N	_N/A
9	Y	_ N	N/A
•	Y	_ N	_N/A
	Y	_N	N/A
ate	d		
of			

Ν

N/A

Υ

	Facility:			
	Date:			
50.	If the healthcare facility did not receive a copy of the manifest signed by the designate facility within 60 days of the date the non-creditable HW pharmaceuticals were accept by the initial transporter, did the facility submit to DEP a handwritten or typed note on t manifest itself, or on an attached sheet of paper, stating that the return copy was not received and explaining the efforts taken to locate the non-creditable HW pharmaceuticals and the results of those efforts? [266.502(i)(2)(i)(A)(2)]	ed	_ N	_ N/A
51.	For a shipment rejected by the designated facility and shipped to an alternate facility, if the healthcare facility did not receive a copy of the manifest signed by the alternate designated facility within 60 days of the date the non-creditable HW pharmaceuticals were accepted by the initial transporter forwarding the shipment from the designated facility to the alternate facility, did the healthcare facility submit a legible copy of the original manifest, indicating that the healthcare facility has not received confirmation of delivery, to DEP? [266.502(i)(2)(ii)(A)(1)]	Y	_ N	_N/A
52.	For a shipment rejected by the designated facility and shipped to an alternate facility, if the healthcare facility did not receive a copy of the manifest signed by the alternate designated facility within 60 days of the date the non-creditable HW pharmaceuticals were accepted by the initial transporter forwarding the shipment from the designated facility to the alternate facility, did the healthcare facility submit to DEP a handwritten of typed note on the manifest itself, or on an attached sheet of paper, stating that the retu copy was not received and explaining the efforts taken to locate the non-creditable HW pharmaceuticals and the results of those efforts? [266.502(i)(2)(i)(A)(2)]	rn	_ N	_ N/A
	GENERAL STANDARDS – POTENTIALLY CREDITABLE PHARMACEUTICALS		_ N/A	
53.	Has the healthcare facility correctly determined whether the potentially creditable pharmaceuticals generated are potentially creditable HW pharmaceuticals? [266.503(a)] Y	N	_N/A
54.	If the healthcare facility had a spill of potentially creditable HW pharmaceuticals was the spill cleaned up immediately and the cleanup material managed as non-creditable HW pharmaceuticals? [266.503(f)]	Y	_ N	_ N/A
	Note: "Potentially creditable" HW pharmaceuticals apply only to prescription pharmace with a reasonable expectation of credit and are: (1) undispensed, (2) in the manuface original container, and (3) are less than one-year past expiration			

	Facility:			
	Date:			
	ACCEPTING POTENTIALLY CREDITABLE HW PHARMACEUTIO FROM OFF-SITE VSQG HEALTHCARE FACILITYN/A		;	
55.	If the healthcare facility is receiving potentially creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility under the control of the same person (as defined in § 260.10) as the VSQG healthcare facility that is sending the potentially creditable HW pharmaceuticals off-site or has a contractual or other documented business relationship whereby the receiving healthcare facility supplies pharmaceuticals to the VSQG healthcare facility? [266.503(b)(1)]	Y	N	N/A
56.	If the healthcare facility is receiving potentially creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility operating under 40 CFR Part 266 Subpart P for its potentially creditable HW pharmaceuticals? [266.503(b)(2)]	Y	N	N/A
57.	If the healthcare facility is receiving potentially creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility managing the potentially creditable HW pharmaceuticals it receives from off-site in compliance with 40 CFR Part 266 Subpart P? [266.503(b)(3)]	Y	N	N/A
58.	If the healthcare facility is receiving potentially creditable HW pharmaceuticals from an off-site VSQG healthcare facility, is the receiving facility keeping records of the potentially creditable HW pharmaceutical shipments it receives for 3 years from the date the shipment is received? [266.503(b)(4)]	Y	N	N/A
	SHIPPING – CREDITABLE HW PHARMACEUTICALS N/A			
59.	Does the healthcare facility send hazardous waste other than potentially creditable HW pharmaceuticals to a reverse distributor? [266.503(c)]	Y	N	N/A
60.	For off-site shipments of potentially creditable HW pharmaceuticals to a reverse distributor, does the healthcare facility keep copies of the confirmation of delivery for 3 years from the date of the shipment? [266.503(e)(1)(i)]	Y	N	N/A
61.	For off-site shipments of potentially creditable HW pharmaceuticals to a reverse distributor, does the healthcare facility keep copies of the shipping papers prepared in accordance with 49 CFR part 172 subpart C, if applicable? [266.503(e)(1)(ii)]	Y	N_	N/A
62.	Are all records readily available upon request by the inspector? [266.503(e)(3)]	Y	_ N_	N/A
63.	For shipment(s) of potentially creditable hazardous waste pharmaceuticals off-site to a reverse distributor, did the healthcare facility comply with all applicable DOT regulation in 49 CFR Parts 171 through 180 for any potentially creditable HW pharmaceutical that meets the definition of hazardous material in 49 CFR 171.8? [266.509(a)]	S	N	N/A
	NOTE : For purposes of the Department of Transportation regulations, a material is considered a hazardous waste if it is subject to the Hazardous Waste Manifest Requirements of the U.S. Environmental Protection Agency specified in 40 CFR part 262. Because a potentially creditable hazardous waste pharmaceutical does not require a manifest, it is not considered hazardous waste under the Department of Transportation regulations.			
64.	Did the healthcare facility receive confirmation (paper or electronic) within 35 days from the date a shipment of potentially creditable HW pharmaceuticals was sent, that the shipment was received and is under the control of the reverse distributor? [266.509(b)]		_ N	N/A
65.	If the healthcare facility did not receive delivery confirmation (paper or electronic) withi 35 days from the date a shipment of potentially creditable HW pharmaceuticals was se to a reverse distributor, did the healthcare facility contact the carrier and the reverse distributor promptly to report the delivery confirmation was not received and determine the status of the shipment? [266.509(c)]	nt	N	N/A

	Facility:				
	Date:				
	DEA CONTROLLED SUBSTANCES – CONDITIONAL EXEMPTION	_ N/A	•		
66.	If the healthcare facility manages any HW pharmaceuticals that are also listed on a schedule of controlled substances by the DEP in 21 CFR Part 1308 using the conditional exemption identified in 40 CFR 266.506(a), were the HW pharmaceuticals managed in compliance with the sewer prohibition of 266.506? [266.506(a)]	Y	_N	N/A	
67.	If the healthcare facility manages any HW pharmaceuticals that are also listed on a schedule of controlled substances by the DEP in 21 CFR Part 1308 using the conditional exemption identified in 40 CFR 266.506(a), were the HW pharmaceuticals collected, stored, transported, and disposed of in compliance with all applicable DEA regulations for controlled substances? [266.506(a)]	Y	_N	N/A	
68.	If the healthcare facility manages any HW pharmaceuticals that are also listed on a schedule of controlled substances by the DEP in 21 CFR Part 1308 using the conditional exemption identified in 40 CFR 266.506(a), were the HW pharmaceuticals destroyed by a method that DEA has publicly deemed in writing to meet their non-retrievable standard of destruction or combusted at a municipal waste combustor or incinerator identified in 40 CFR 266.506(b)(3)? [266.506(a)]	Y	<u>N</u>	N/A	